These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

640 related items for PubMed ID: 12825969

  • 1. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.
    Kontoghiorghes GJ, Neocleous K, Kolnagou A.
    Drug Saf; 2003; 26(8):553-84. PubMed ID: 12825969
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Deferasirox for managing iron overload in people with thalassaemia.
    Meerpohl JJ, Antes G, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D.
    Cochrane Database Syst Rev; 2012 Feb 15; (2):CD007476. PubMed ID: 22336831
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Des Devel Ther; 2016 Feb 15; 10():465-81. PubMed ID: 26893541
    [Abstract] [Full Text] [Related]

  • 8. Pharmacotherapy of iron overload in thalassaemic patients.
    Ceci A, Felisi M, De Sanctis V, De Mattia D.
    Expert Opin Pharmacother; 2003 Oct 15; 4(10):1763-74. PubMed ID: 14521486
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA, Foster RH.
    Drugs; 1999 Sep 15; 58(3):553-78. PubMed ID: 10493280
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical use, therapeutic aspects and future potential of deferiprone in thalassemia and other conditions of iron and other metal toxicity.
    Kontoghiorghes GJ.
    Drugs Today (Barc); 2001 Jan 15; 37(1):23-35. PubMed ID: 12783095
    [Abstract] [Full Text] [Related]

  • 13. Chelation protocols for the elimination and prevention of iron overload in thalassaemia.
    Kolnagou A, Kontoghiorghes GJ.
    Front Biosci (Landmark Ed); 2018 Jan 01; 23(6):1082-1098. PubMed ID: 28930590
    [Abstract] [Full Text] [Related]

  • 14. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ.
    Cochrane Database Syst Rev; 2007 Jul 18; (3):CD004839. PubMed ID: 17636775
    [Abstract] [Full Text] [Related]

  • 15. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
    Kolnagou A, Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Res (Stuttg); 2017 Jul 18; 67(7):404-411. PubMed ID: 28320041
    [Abstract] [Full Text] [Related]

  • 16. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
    Kontoghiorghes GJ, Eracleous E, Economides C, Kolnagou A.
    Curr Med Chem; 2005 Jul 18; 12(23):2663-81. PubMed ID: 16305464
    [Abstract] [Full Text] [Related]

  • 17. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May 18; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 18. Iron chelation therapy.
    Hoffbrand AV, Wonke B.
    J Intern Med Suppl; 1997 May 18; 740():37-41. PubMed ID: 9350180
    [Abstract] [Full Text] [Related]

  • 19. New chelation therapies and emerging chelating drugs for the treatment of iron overload.
    Kontoghiorghes GJ.
    Expert Opin Emerg Drugs; 2006 Mar 18; 11(1):1-5. PubMed ID: 16503822
    [Abstract] [Full Text] [Related]

  • 20. Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.
    Kontoghiorghes GJ.
    Indian J Pediatr; 1993 Mar 18; 60(4):485-507. PubMed ID: 8262586
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.